Neureka for Epilepsy
Early Stage
Epilepsy care reimagined
Overview
Raised: $75,071
Total Commitments ($USD)
Platform
Republic
Start Date
02/14/2023
Close Date
04/15/2023
Min. Goal
$25,000
Max. Goal
$1,235,000
Min. Investment
$150
Security Type
SAFE
Series
Seed
SEC Filing Type
RegCF
Valuation Cap
$25,000,000
Discount
20%
Rolling Commitments ($USD)
Status
Active
Reporting Date
03/27/2023
Days Remaining
19
% of Min. Goal
300%
% of Max. Goal
6%
Likelihood of Max
Avg. Daily Raise
$1,831
# of Investors
77
Momentum
Create a free account today to gain access to KingsCrowd analytics.
Year Founded
2018
Industry
Healthcare & Pharmaceuticals
Tech Sector
HealthTech
Distribution Model
B2B/B2C
Margin
Low
Capital Intensity
Low
Neureka for Epilepsy, with a valuation of $25 million, is raising funds on Republic. The company provides AI-powered wearable devices for on-demand epilepsy care. The wearable device captures health data, connects patients with their care teams, and empowers doctors with data to make better treatment decisions. Neureka for Epilepsy is backed by ten years of R&D and is accelerating its epilepsy center partnerships and B2C market traction. Ray Iskander and Parisa Sabetian founded Neureka for Epilepsy in February 2018. The current crowdfunding campaign has a minimum target of $25,000 and a maximum target of $1.24 million. The campaign proceeds will be used for new product marketing, research and development, new hires, and general working capital.
Summary Profit and Loss Statement
| Most Recent Year | Prior Year | |
|---|---|---|
|
Revenue |
$0 |
$0 |
|
COGS |
$0 |
$0 |
|
Tax |
$0 |
$0 |
| ||
| ||
|
Net Income |
$-1,393,497 |
$-962,316 |
Summary Balance Sheet
| Most Recent Year | Prior Year | |
|---|---|---|
|
Cash |
$281,299 |
$64,459 |
|
Accounts Receivable |
$0 |
$0 |
|
Total Assets |
$286,340 |
$71,179 |
|
Short-Term Debt |
$50,065 |
$34,704 |
|
Long-Term Debt |
$20,171 |
$42,167 |
|
Total Liabilities |
$70,236 |
$76,871 |
Financials as of: 02/14/2023
Create a free account today to gain access to KingsCrowd analytics.
Upgrade to gain access
Pay Monthly
Annually (Save 17%)
-
$12.42 /month
billed annually - Free portfolio tracking and KingsCrowd's quantitative ratings on all raises.
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings (excluding risk)
- Advanced company search ( with ratings)
- Markets page filters and historical industry data
- Get Edge Annual
Edge
-
$41.58 /month
billed annually - Full site access including KingsCrowd's qualitative analyst reports.
- Plan Includes:
- Everything in Edge, plus
- Full access to detailed Analyst Reports (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
- Search and filter based on Analyst Reports
- In-depth risk ratings for every raise
- Get Edge Pro Annual
Edge Pro
Already a member? Log in here.
Ratings 
Wall Street has Morningstar, S&P, and Bloomberg
The equity crowdfunding market has KingsCrowd.
Analyst Report
Pending Review
Are you the founder of Neureka for Epilepsy? Create your account today to claim this raise page.